Anand Kiran Parikh - 15 Jun 2026 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: President and CEO, Director
Issuer ticker: SNSE
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 16:38:38 UTC
Prior SEC filing: 19 Feb 2026
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Josiah Craver, Attorney-in-Fact

Key filing fact

Anand Kiran Parikh filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 16 Jun 2026.

Key facts

This page summarizes Anand Kiran Parikh's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2026, 16:38.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111813 Primary reporting owner

Parikh Anand Kiran

Relationship: President and CEO, Director
Address: C/O FAETH THERAPEUTICS, INC., 701 TILLERY STREET #12 #1010, AUSTIN
Signature: /s/ Josiah Craver, Attorney-in-Fact
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNSE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +761,428
Change %
Price
Shares after: 761,428
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNSE transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -761
Change %: -100%
Price
Shares after: 0
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 761,428
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.

Footnote F2

Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").

Footnote F3

Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock.